2.315
price up icon10.77%   0.225
 
loading
Humacyte Inc stock is traded at $2.315, with a volume of 2.91M. It is up +10.77% in the last 24 hours and down -13.30% over the past month. Humacyte Inc is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Advanced Organ Systems, Advanced Tissue Constructs.
See More
Previous Close:
$2.09
Open:
$2.11
24h Volume:
2.91M
Relative Volume:
0.61
Market Cap:
$414.17M
Revenue:
-
Net Income/Loss:
$-110.78M
P/E Ratio:
-2.1636
EPS:
-1.07
Net Cash Flow:
$-75.59M
1W Performance:
+3.81%
1M Performance:
-13.30%
6M Performance:
-54.16%
1Y Performance:
-56.89%
1-Day Range:
Value
$2.08
$2.395
1-Week Range:
Value
$2.08
$2.395
52-Week Range:
Value
$1.15
$9.79

Humacyte Inc Stock (HUMA) Company Profile

Name
Name
Humacyte Inc
Name
Phone
919-313-9633
Name
Address
2525 EAST NORTH CAROLINA HIGHWAY 54, DURHAM
Name
Employee
220
Name
Twitter
Name
Next Earnings Date
2025-03-28
Name
Latest SEC Filings
Name
HUMA's Discussions on Twitter

Compare HUMA with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
HUMA
Humacyte Inc
2.315 414.17M 0 -110.78M -75.59M -1.07
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
452.96 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
539.18 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
324.24 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
551.27 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
245.57 28.51B 3.81B -644.79M -669.77M -6.24

Humacyte Inc Stock (HUMA) Upgrades & Downgrades

Date Action Analyst Rating Change
May-14-25 Resumed H.C. Wainwright Buy
Dec-20-24 Reiterated H.C. Wainwright Buy
Dec-11-23 Initiated H.C. Wainwright Buy
Aug-14-23 Upgrade Piper Sandler Underweight → Neutral
Jun-22-23 Initiated Cantor Fitzgerald Overweight
May-16-22 Downgrade Piper Sandler Overweight → Underweight
Oct-29-21 Initiated Cowen Outperform
Sep-24-21 Initiated Oppenheimer Outperform
Sep-22-21 Initiated BTIG Research Buy
Sep-16-21 Initiated Piper Sandler Overweight
View All

Humacyte Inc Stock (HUMA) Latest News

pulisher
Jun 18, 2025

Humacyte, Inc. (HUMA) Gains As Market Dips: What You Should Know - Yahoo Finance

Jun 18, 2025
pulisher
Jun 17, 2025

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of January 17, 2025 in Humacyte, Inc. LawsuitHUMA - ACCESS Newswire

Jun 17, 2025
pulisher
Jun 11, 2025

Humacyte: Revenue Ramp From Symvess Incoming (NASDAQ:HUMA) - Seeking Alpha

Jun 11, 2025
pulisher
Jun 09, 2025

Humacyte (HUMA) Maintains "Buy" Rating with $25 Price Target | H - GuruFocus

Jun 09, 2025
pulisher
Jun 09, 2025

Humacyte (HUMA) Phase 3 Trial Highlights Advantages of Engineered Vessel for Hemodialysis | HUMA Stock News - GuruFocus

Jun 09, 2025
pulisher
Jun 09, 2025

Humacyte, Inc. Announces the Results from Its V007 Pivotal Phase 3 Clinical Trial of the Acellular Tissue Engineered Vessel - MarketScreener

Jun 09, 2025
pulisher
Jun 09, 2025

Results from Humacyte's V007 Pivotal Phase 3 AV Access Study Highlighted by Presentation at the Society for Vascular Surgery Meeting - The Manila Times

Jun 09, 2025
pulisher
Jun 09, 2025

Phase 3 Trial: Humacyte Vessel Outperforms Standard Dialysis Access in High-Risk Patients | HUMA Stock News - Stock Titan

Jun 09, 2025
pulisher
Jun 09, 2025

Humacyte Paradoxically Scales Back As Symvess Begins Its Long Journey (NASDAQ:HUMA) - Seeking Alpha

Jun 09, 2025
pulisher
Jun 06, 2025

Humacyte, Inc. (NASDAQ:HUMA) Short Interest Up 20.7% in May - Defense World

Jun 06, 2025
pulisher
Jun 04, 2025

Nuveen Asset Management LLC Lowers Stake in Humacyte, Inc. (NASDAQ:HUMA) - Defense World

Jun 04, 2025
pulisher
Jun 03, 2025

Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Humacyte, Inc. (HUMA) Shareholders - ACCESS Newswire

Jun 03, 2025
pulisher
Jun 03, 2025

Cetera Investment Advisers Buys 9,134 Shares of Humacyte, Inc. (NASDAQ:HUMA) - Defense World

Jun 03, 2025
pulisher
Jun 02, 2025

Humacyte (HUMA) to Present Phase 3 Trial Results at Vascular Sur - GuruFocus

Jun 02, 2025
pulisher
Jun 02, 2025

Humacyte Clinical Results in High-Risk Dialysis Patients from V007 Pivotal Phase 3 - TradingView

Jun 02, 2025
pulisher
Jun 02, 2025

Breakthrough: Humacyte's Bioengineered Vessel Outperforms Standard Treatment in Phase 3 Dialysis Trial - Stock Titan

Jun 02, 2025
pulisher
Jun 02, 2025

Humacyte, Inc. (NASDAQ:HUMA) Shares Acquired by ProShare Advisors LLC - Defense World

Jun 02, 2025
pulisher
Jun 02, 2025

BNP Paribas Financial Markets Buys Shares of 14,613 Humacyte, Inc. (NASDAQ:HUMA) - Defense World

Jun 02, 2025
pulisher
Jun 01, 2025

Humacyte, Inc. (NASDAQ:HUMA) Shares Bought by Bank of America Corp DE - Defense World

Jun 01, 2025
pulisher
May 31, 2025

Deutsche Bank AG Purchases 26,419 Shares of Humacyte, Inc. (NASDAQ:HUMA) - Defense World

May 31, 2025
pulisher
May 30, 2025

Is Humacyte, Inc. (HUMA) a Buy as Wall Street Analysts Look Optimistic? - Nasdaq

May 30, 2025
pulisher
May 29, 2025

Humacyte, Inc. (NASDAQ:HUMA) Q1 2025 Earnings Call Transcript - MSN

May 29, 2025
pulisher
May 29, 2025

Millennium Management LLC Sells 348,653 Shares of Humacyte, Inc. (NASDAQ:HUMA) - Defense World

May 29, 2025
pulisher
May 28, 2025

$HUMA - Binance

May 28, 2025
pulisher
May 22, 2025

Brokers Suggest Investing in Humacyte, Inc. (HUMA): Read This Before Placing a Bet - MSN

May 22, 2025
pulisher
May 22, 2025

Northern Trust Corp Purchases 92,708 Shares of Humacyte, Inc. (NASDAQ:HUMA) - Defense World

May 22, 2025
pulisher
May 21, 2025

Is Humacyte (NASDAQ:HUMA) A Risky Investment? - simplywall.st

May 21, 2025
pulisher
May 21, 2025

Humacyte, Inc. (NASDAQ:HUMA) Receives $11.71 Average PT from Brokerages - Defense World

May 21, 2025
pulisher
May 20, 2025

Humacyte at H.C. Wainwright Conference: Promising Developments in SimVess By Investing.com - Investing.com Nigeria

May 20, 2025
pulisher
May 20, 2025

Humacyte at H.C. Wainwright Conference: Promising Developments in SimVess - Investing.com Australia

May 20, 2025
pulisher
May 19, 2025

Humacyte to Present at the H.C. Wainwright 3rd Annual BioConnect Investor Conference at Nasdaq - The Manila Times

May 19, 2025
pulisher
May 19, 2025

Humacyte CEO Reveals Latest Bioengineered Tissue Developments at Elite Nasdaq Conference - Stock Titan

May 19, 2025
pulisher
May 18, 2025

Price T Rowe Associates Inc. MD Has $172,000 Stock Holdings in Humacyte, Inc. (NASDAQ:HUMA) - Defense World

May 18, 2025
pulisher
May 17, 2025

What is HC Wainwright’s Estimate for Humacyte Q2 Earnings? - Defense World

May 17, 2025
pulisher
May 15, 2025

Humacyte’s Earnings Call Highlights Success and Challenges - TipRanks

May 15, 2025
pulisher
May 14, 2025

Humacyte, Inc. (HUMA) Reports Q1 Loss, Lags Revenue Estimates - MSN

May 14, 2025
pulisher
May 14, 2025

Humacyte (HUMA) Receives Buy Rating and $4.00 Price Target from HC Wainwright & Co. | HUMA Stock News - GuruFocus

May 14, 2025
pulisher
May 14, 2025

Humacyte (HUMA) Gains Buy Rating with $4 Target | HUMA Stock New - GuruFocus

May 14, 2025
pulisher
May 14, 2025

Benchmark cuts Humacyte stock target to $14, maintains Buy rating By Investing.com - Investing.com South Africa

May 14, 2025
pulisher
May 14, 2025

Humacyte (HUMA) Reports Lower-Than-Expected Q1 Revenue Amid Symv - GuruFocus

May 14, 2025
pulisher
May 14, 2025

Humacyte, Inc.: Spare Parts for People - Outsider Club

May 14, 2025
pulisher
May 14, 2025

Humacyte outlines expansion of Symvess to 45 hospitals while targeting BLA submission for ATEV in dialysis by 2026 - MSN

May 14, 2025
pulisher
May 14, 2025

Humacyte (HUMA) Gains Buy Rating with $4 Target | HUMA Stock News - GuruFocus

May 14, 2025
pulisher
May 14, 2025

Benchmark cuts Humacyte stock target to $14, maintains Buy rating - Investing.com

May 14, 2025
pulisher
May 14, 2025

Humacyte (HUMA) Price Target Reduced by Benchmark Amid Positive Outlook | HUMA Stock News - GuruFocus

May 14, 2025
pulisher
May 14, 2025

Humacyte (HUMA) Focuses on Symvess Launch and Expansion Plans - GuruFocus

May 14, 2025
pulisher
May 14, 2025

Humacyte price target lowered to $14 from $17 at Benchmark - TipRanks

May 14, 2025
pulisher
May 14, 2025

Durham firm with battered stock cuts jobs to save cash - The Business Journals

May 14, 2025
pulisher
May 14, 2025

Humacyte Reports Q1 2025 Earnings and Strategic Progress - TipRanks

May 14, 2025
pulisher
May 13, 2025

Earnings call transcript: Humacyte Q1 2025 beats EPS forecast, stock surges - Investing.com Nigeria

May 13, 2025
pulisher
May 13, 2025

Humacyte, Inc. SEC 10-Q Report - TradingView

May 13, 2025

Humacyte Inc Stock (HUMA) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

Humacyte Inc Stock (HUMA) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
Sander Dale A.
CFO and Chief Corp. Deve. Off.
Apr 10 '25
Buy
1.53
20,000
30,600
40,600
Parikh Shamik J
Chief Medical Officer
Apr 10 '25
Buy
1.55
7,500
11,625
7,500
Sebelius Kathleen
Director
Apr 08 '25
Buy
1.32
50,000
66,000
91,207
Green Charles Bruce
Director
Apr 08 '25
Buy
1.29
6,000
7,740
8,400
Constantino Michael T.
Director
Apr 07 '25
Buy
1.26
16,000
20,160
32,950
Constantino Michael T.
Director
Dec 04 '24
Buy
4.39
4,600
20,181
16,950
Niklason Laura E
President, CEO and Director
Nov 19 '24
Buy
4.44
1,797
7,979
243,851
Dougan Brady W
Director
Nov 19 '24
Buy
4.44
1,797
7,979
243,851
Niklason Laura E
President, CEO and Director
Nov 18 '24
Sale
4.44
811,172
3,601,604
2,419,712
Niklason Laura E
President, CEO and Director
Nov 19 '24
Sale
4.34
427,459
1,855,172
1,992,253
$20.80
price up icon 0.77%
$35.76
price down icon 0.76%
$21.48
price up icon 0.96%
$98.46
price down icon 2.29%
$108.74
price up icon 2.15%
biotechnology ONC
$245.58
price up icon 1.50%
Cap:     |  Volume (24h):